Conviction: Medium
Status: Watching — RSI 36.3 (data as of 02/23), approaching entry zone, price ~$98.61
Quick Snapshot
| Signal |
Reading |
| Overall |
🟡 RSI 36.3 (last OHLC: 02/23) — approaching oversold. Price $98.61, +2.3% in 7 days, -2.0% in 30 days. SMA20 $100.61. Near SMA. Alert at $92 still active. |
| Moat |
Moderate-Wide — scale and switching costs, but execution has lagged peers |
| Key insight |
MDT data stale (last entry 02/23). The 7D improved to +2.3% from +1.8% (last read), suggesting a slight upward bounce. RSI at 36.3 is still above the 30-35 entry zone. Need RSI to drop to 30-35 WITH price in $88-94 zone for ideal entry. Currently not in that zone. |
Action Matrix
| Action |
Level |
Why |
| Current |
🔍 Watch |
RSI 36.3 approaching entry zone but price not yet at ideal $88-94. Alert at $92. |
| Entry Zone |
$88 - $94 |
~10-15% pullback from current ~$98; prior support zone |
| Stop-Loss |
$79 (-20%) |
Below 52-week low ($79.55) — thesis-killer territory |
| Target 1 |
$108 (+10%) |
Return to consensus analyst target zone |
| Target 2 |
$117 (+19%) |
All-time high (Sept 2021) — full recovery scenario |
Price Data
| Stock |
Price |
1D |
7D |
30D |
3M |
52wkHi |
RSI |
Status |
Action |
| MDT |
$98.61 |
+1.8% |
+2.3% |
-2.0% |
— |
-4.4% |
36 |
🟡 Approaching Oversold |
🔍 Watch |
Note: OHLC data last updated 2026-02-23. RSI 36.3, SMA20 $100.61.
Price vs Last Deep Dive (02/26)
| Metric |
02/26 |
03/03 |
Change |
| Price |
$98.61 |
$98.61 |
$0.00 (data stale since 02/23) |
| RSI |
36.3 |
36.3 |
0.0 (stale) |
| SMA20 |
$100.61 |
$100.61 |
Unchanged (stale) |
| vs SMA |
-2.0% |
-2.0% |
Stale |
Update (03/03): MDT OHLC data has not refreshed since 02/23. The 7D reading (+2.3% vs prior +2.4% on 02/26 file) shows effectively no change from stale data. RSI at 36.3 still above the 30-35 entry trigger. Price at $98.61 is still above the $88-94 entry zone. No change in action or analysis.
Company Overview
One-Liner
Medtronic is the world's largest standalone medical device company by revenue — a $34B/year enterprise spanning heart rhythm management, surgical robotics, spinal implants, neurostimulation, and diabetes technology operating in 150+ countries.
Business Model
| Question |
Answer |
| What they sell |
Implantable and non-implantable medical devices, capital equipment, disposables, software systems |
| Who pays |
Hospitals, health systems, surgical centers, government payers |
| Revenue model |
Mix of capital equipment (upfront) + high-margin disposables/consumables (recurring), service contracts |
| How sticky |
High — physician training on specific platforms creates lock-in; hospital systems make multi-year purchasing commitments |
Key Segments (Q3 FY2026 — Quarter Ended January 23, 2026)
| Segment |
Q3 Revenue |
Q3 Organic Growth |
Key Products |
Notes |
| Cardiovascular |
$3.457B |
+10.6% |
PFA/Affera system, TAVR (Evolut), cardiac monitoring |
Star segment — PFA +80% global, +137% US |
| Neuroscience |
$2.558B |
+2.5% |
Spinal fusion/implants, neuro-stimulation, ENT |
Slowest growth |
| Medical Surgical |
$2.173B |
+2.7% |
Hugo surgical robot, endoscopy |
Hugo FDA cleared Feb 2026 — early innings |
| Diabetes |
$796M |
+8.3% |
MiniMed CGM, insulin pumps |
Being spun off as MiniMed (mid-late 2026) |
Investment Thesis
Bull Case — The Inflection Is Real
| Argument |
Evidence |
Conviction |
| PFA is a genuine multi-year growth driver |
Cardiac Ablation Solutions +80% global, +137% US in Q3 FY26. |
🟢 High |
| MiniMed spinoff unlocks value and focus |
Removing GLP-1 narrative overhang; 100+ bps margin uplift post-spinoff. |
🟢 High |
| Hugo FDA clearance opens $13B+ robot market |
Just cleared for urologic procedures Feb 2026. |
🟡 Medium (early) |
| Dividend aristocrat with 48 years of increases |
$2.84/year annual dividend (~2.9% yield at current price). |
🟢 High |
| Valuation is modest vs. peer group |
MDT P/E ~26x forward — cheapest large-cap medtech. BSX at 57x. SYK at ~35x. |
🟢 Medium-High |
Bear Case — The Value Trap Scenario
| Argument |
Evidence |
Risk Level |
| 10-year history of underperformance |
MDT all-time high was Sept 2021 ($117.57). Still 16% below that. |
🟠 Real |
| Hugo is years from meaningful revenue |
ISRG has 10,763+ installed systems. Hugo just got first FDA clearance Feb 2026. |
🟠 Real |
| Neuroscience / Spine is a structural drag |
Spine market mature, price-deflationary. |
🟡 Medium |
Technical Setup
| Indicator |
Value |
Signal |
| Price |
$98.61 |
Still above entry zone |
| RSI (14) |
36.3 (last valid: 02/23) |
🟡 Approaching Oversold — not yet at entry trigger |
| SMA20 |
$100.61 |
Price -2.0% below SMA — very close |
| 52-week range |
$79.55 - $103.18 |
Near top of range |
| YTD performance |
~+22% |
Significant outperformance YTD |
Key Technical Levels
| Level |
Price |
Notes |
| Immediate support |
$93-95 |
Post-Q3 earnings gap-up base |
| Entry zone |
$88-94 |
RSI trigger + price target together |
| Strong support |
$79-82 |
52-week low zone |
| Resistance 1 |
$100.61 |
SMA20 — just above |
| Resistance 2 |
$103.18 |
52-week high in data window |
| Long-term target |
$108-117 |
Analyst consensus ($111.77 avg) to ATH recovery |
Catalysts & Timing
| Date |
Event |
Impact |
Watch For |
| Mid-2026 |
MiniMed Diabetes spinoff/IPO |
🟢🟢 |
Removes GLP-1 narrative; potential value unlock |
| Q4 FY26 Earnings (~May 2026) |
Final quarter before FY26 close |
🟢 |
Whether organic growth stays 5.5%+ |
| FY2026-FY2027 |
Hugo US commercial placements |
🟢 |
First disclosed Hugo placement/revenue data |
| Ongoing |
PFA (Affera) market share vs BSX |
🟢 |
Can MDT sustain majority share in new EP labs? |
Entry Strategy
| Strategy |
Details |
| Current |
Watch — RSI approaching 35, price still above entry zone |
| Alert |
$92 — entry zone bottom |
| Entry zone |
$88 - $94 (~10-15% pullback) |
| RSI target |
RSI < 35 with price in $88-94 zone |
| Stop |
$79 (-20% from entry zone) |
Research Log
| Date |
Update |
| 2026-02-22 |
Created deep dive. MDT not in stonks data system. Price ~$97.58 (market data). RSI ~58 (estimated). Q3 FY26 showed strongest enterprise growth in 10 quarters (+6.0% organic). PFA franchise +80%. Hugo FDA cleared for urology Feb 2026. Conviction: Medium. Action: Watch, alert at $92. |
| 2026-02-26 |
Fresh OHLC data now available. Price $98.61 (+1.1% vs prior). RSI fresh at 36.3. SMA20 $100.61. RSI drop from ~58 to 36.3 shows post-Q3 digestion underway. -2.4% 7D, -2.0% 30D. Getting closer to entry zone but not there yet. Action: Watch, maintain $92 alert. |
| 2026-03-03 |
OHLC data stale since 02/23. No change in data. 7D +2.3% (marginal improvement). RSI 36.3, price $98.61 above entry zone. Action unchanged: Watch, $92 alert active. |
The Gold
Key Discoveries
| Discovery |
Implication |
| RSI dropped from ~58 to 36.3 |
Post-Q3 enthusiasm cooling — approaching entry territory |
| SMA20 $100.61, price $98.61 (only -2% gap) |
Right at moving average — clean technical level |
| 52wk high $103.18 only 4.4% above |
Upside is toward analyst targets ($108-117) |
| +2.3% 7D with RSI at 36 |
Price holding while RSI declined — constructive |
Open Questions
- Is RSI still 36.3 or has it moved toward entry zone?
- What are the specific Hugo US placement numbers from Q3 FY26 earnings call?
- Is Affera genuinely winning majority share in new EP lab openings?
- What multiple will MiniMed trade at post-spinoff?
Mistakes (If Applicable)
| Mistake |
Lesson |
| N/A — first deep dive, no capital deployed |
Wait for pullback to $88-94 — RSI at 36 is better than 58 but entry zone is still below current price |
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.